Open an account

Belite Bio

BLTE · NASDAQ

$154.45+$7.11 (+4.83%)TodayMarket closed ·
Prev close $147.34

About BLTE

Belite Bio, Inc. engages in the research and development of drugs. The company is headquartered in San Diego, California and currently employs 41 full-time employees. The company went IPO on 2022-04-29. The firm is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.

Employees
41
Headquarters
San Diego, California
Listed
Apr 29, 2022
Sector
Health Care
Industry
Pharmaceuticals
Website
belitebio.com

BLTE key statistics

Market cap
5.93B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
168.26K
Volume
209.76K
Open price
$148.69
High today
$156.04
Low today
$148.16
52 Week high
$200.00
52 Week low
$86.57

Belite Bio (BLTE) at a glance

Belite Bio (BLTE) last traded at $154.45, with a market cap of 5.93B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $148.16 and $156.04. The current price is 4.2% above the day's low and 1.0% below its high.

Volume so far is 209.76K shares, above the average of 168.26K shares a day.

Over the past year Belite Bio has ranged from $86.57 to $200.00, and now sits 60% of the way up that range.

Belite Bio met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported -$0.70 per share against an estimate of -$0.8045.

The average analyst price target is $233.47, 51.2% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 7 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 11 analystsAvg $233.47
Low
$186.85
Now
$154.45
High
$318.15

BLTE earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 8.8% on average.

  1. Q3 FY24: reported -$0.28 per share against an estimate of -$0.2938
  2. Q4 FY24: reported -$0.32 per share against an estimate of -$0.314
  3. Q1 FY25: reported -$0.45 per share against an estimate of -$0.381
  4. Q2 FY25: reported -$0.50 per share against an estimate of -$0.4259
  5. Q3 FY25: reported -$0.65 per share against an estimate of -$0.4973
  6. Q4 FY25: reported -$0.70 per share against an estimate of -$0.5572
  7. Q1 FY26: reported -$0.68 per share against an estimate of -$0.6484
  8. Q2 FY26: reported -$0.70 per share against an estimate of -$0.8045

BLTE news

  • Vandana Singh

    Why Is Belite Bio Stock Soaring Friday?

  • Vandana Singh

    Why Is Belite Bio Stock Gaining Monday?

  • Vandana Singh

    Belite Bio Scores First Successful Phase 3 Trial For Rare Vision-Loss Disease

  • Earnings Outlook For Belite Bio

  • Belite Bio's Earnings Outlook

  • Insights into Belite Bio's Upcoming Earnings

Similar companies

Companies in the same industry as Belite Bio

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.